Infections associated with bacteria of the genus Elizabethkingia in children with cystic fibrosis and operated on due to congenital heart defects: microbiological features and clinical significance

Bacteria of the genus Elizabethkingia are gram-negative rod-shaped bacteria found throughout the world. The main reservoir for representatives of this genus is water and soil. Despite this, more and more clinical data are emerging indicating the role of these representatives in the development of nosocomial and community-acquired infections, most often sepsis and meningitis. Risk groups include newborns, children, the elderly, patients with cystic fibrosis (CF) and people with immunodeficiencies. Infections associated with Elizabethkingia spp. are generally associated with high mortality rates (18.2-41%) and are most often observed in neonates and immunocompromised patients. Members of the genus Elizabethkingia are naturally resistant to many of the antibiotics traditionally prescribed for infections with gram-negative bacteria. Timely diagnosis and early initiation of appropriate combination therapy are critical in the treatment of such infections. During the period 2018-2023. Isolation of bacteria of the genus Elizabethkingia was observed from biological material obtained from children with CF and 8 newborn children with a cardiac profile who underwent life-saving surgery due to the presence of congenital heart defects. Bacteria of the genus Elizabethkingia were isolated from 15 patients with CF, of which repeat cultures were noted in five patients; 28 strains were identified during the specified period. Of these, in 2018 and 2020 there were 2 strains each, 2019-13, 2021-6 and 2022-5 strains. In the examined newborns, isolation of these bacteria was detected in 4 patients in 2021, in 3 patients in 2022, and in one patient in 2023, respectively. Bacteria of the genus Elizabethkingia are relatively new and poorly studied pathogens of nosocomial infections associated with a high risk of complications and mortality in premature newborns and immunocompromised patients, which requires increased attention from both medical microbiologists and clinicians of various profiles.

children, newborns, cystic fibrosis, Elizabethkingia, surgical infections, sepsis

1. Aldoghaim F. S., Kaabia N., Alyami A. M. et.al. Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) bacteraemia: a series of 12 cases at Prince Sultan Military Medical City KSA. New Microbes New Infect. 2019; Oct; 25(32):100617. doi: 10.1016/j.nmni.2019.100617.

2. Kanashenko M. E., Kartsev N. N., Mitsevich I. P. et al. Elizabethkingia meningoseptica as a significant clinical pathogene. Bacteriology. 2019; 4(1): 58-63. (In Russ.). doi: 10.20953/2500-1027-2019-1-58-63.@@ Канашенко М. Е., Карцев Н. Н., Мицевич И. П. и др. Elizabethkingia meningoseptica как значимый клинический патоген. Бактериология. 2019; 4(1): 58-63. doi: 10.20953/2500-1027-2019-1-58-63.

3. Waleed M. S., Amba V., Varughese A. A., Pathalapati R. Elizabethkingia meningoseptica Bacteremia and Meningitis: A Case Report. Cureus. 2021; Nov;13(11): e19275. doi: 10.7759/cureus.19275.

4. Hsu M. S., Liao C. H., Huang Y. T. et al. Clinical features, antimicrobial susceptibilities, and outcomes of Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) bacteremia at a medical center in Taiwan, 1999-2006. Eur J Clin Microbiol Infect Dis. 2011; Oct;30(10):1271-8. doi: 10.1007/s10096-011-1223-0.

5. Adachi A., Mori T., Simizu T. et al. Chryseobacterium meningosepticum septicemia in a recipient of allogeneic cord blood transplantation. Scand J Infect Dis. 2004; 36(6-7):539-40. doi: 10.1080/ 00365540410020587.

6. Kirby J. T., Sader H. S., Walsh T. R., Jones R. N. Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: Report from the SENTRY antimicrobial surveillance program (1997-2001). J Clin Microbiol. 2004; Jan; 42(1):445-8. doi: 10.1128/jcm.42.1.445-448.2004.

7. Güngör S., Ozen M., Akinci A., Durmaz R. A Chryseobacterium meningosepticum outbreak in a neonatal ward. Infect Control Hosp Epidemiol. 2003; Aug; 24(8):613-7. doi: 10.1086/502261.

8. Rossolini G. M., Franceschini N., Riccio M. L. et al. Characterization and sequence of the Chryseobacterium (Flavobacterium) meningosepticum carbapenemase: a new molecular class B beta-lactamase showing a broad substrate profile. Biochem J. 1998; May; 15(332):145-52. doi: 10.1042/bj3320145.

9. Ceyhan M., Celik M. Elizabethkingia meningosepticum (Chryseobacterium meningosepticum) infections in Children.Int J Pediatr. 2011:215237. doi: 10.1155/2011/215237.

10. Bellais S., Poire L., Naas T. et al. Genetic biochemical analysis and distribution of the Ambler class A-lactamase CME-2, responsible for extended spectrum cephalosporin resistance in Elizabethkingae (Flavobacterium) meningosepticum. Antimicrob Agents Chemother. 2000; Jan; 44(1):1-9. doi: 10.1128/AAC.44.1.1-9.2000.

11. Chen G. X., Zhang R. H., Zhou W. Heterogeneity of metallo-β-lactamases in clinical isolates of Elizabethkingae meningosepticum from Hangzhou China. J Antimicrob Chemother. 2006; Apr; 57(4):750-2. doi: 10.1093/jac/dkl019.

12. González L. J., Vila A. J. Carbapenem Resistance in Elizabethkingia meningoseptica Is Mediated by Metallo-β-Lactamase BlaB. Antimicrob Agents Chemother. 2012; Apr; 56(4):1686-92. doi: 10.1128/AAC.05835-11.

13. Lau S. K., Chow W. N., Foo C. H. et al. Elizabethkingia anopheles bacteremia is associated with clinically significant infections and high mortality. Sci Rep. 2016; May; 17(6):26045. doi: 10.1038/srep26045.

14. Kim K. K., Kim M. K., Lim J. H. et al. Transfer of Chryseobacterium meningosepticum and Chryseobacterium miricola to Elizabethkingia gen. nov. as Elizabethkingia meningoseptica comb. nov. and Elizabethkingia miricola comb. nov.Int J Syst Evol Microbiol. 2005; May; 55(Pt. 3):1287-93. doi: 10.1099/ ijs.0.63541-0.

15. Chan J. C., Chong C. Y., Thoon K. C. et al. Invasive paediatric Elizabethkingia meningoseptica infections are best treated with a combination of piperacillin/tazobactam and trimethoprim/sulfamethoxazole or fluoroquinolone. J Med Microbiol. 2019; Aug; 68(8):1167-1172. doi: 10.1099/jmm.0.001021.

16. de Carvalho Filho É. B., Marson F. A.L., Levy C. E. Challenges in the identification of Chryseobacterium indologenes and Elizabethkingia meningoseptica in cases of nosocomial infections and patients with cystic fibrosis. New Microbes New Infect. 2017; Sep; 13(20):27-33. doi: 10.1016/j.nmni.2017.09.002.

17. Frost F., Nazareth D. Case Report: First report of Elizabethkingia miricola infection in a patient with cystic fibrosis. F1000Res. 2018; Apr; 10(7):440. doi: 10.12688/f1000research.14441.2.

18. Zajmi A., Teo J., Yeo C. C. Epidemiology and Characteristics of Elizabethkingia spp. Infections in Southeast Asia. Microorganisms. 2022; Apr; 10(5):882. doi: 10.3390/microorganisms10050882.

19. Fraser S. L., Jorgensen J. H. Reappraisal of the antimicrobial susceptibilities of Chryseobacterium and Flavobacterium species and methods for reliable susceptibility testing. Antimicrob Agents Chemother. 1997; Dec; 41(12):2738-41. doi: 10.1128/AAC.41.12.2738.

20. Lin P. Y., Chen H. L., Huang C. T. et al. Biofilm production, use of intravascular indwelling catheters and inappropriate antimicrobial therapy as predictors of fatality in Chryseobacterium meningosepticum bacteraemia.Int J Antimicrob Agents. 2010; Nov; 36(5):436-40. doi: 10.1016/j.ijantimicag. 2010.06.033.

21. Mirza H. C., Tuncer Ö., Ölmez S. et al. Clinical Strains of Chryseobacterium and Elizabethkingia spp. Isolated from Pediatric Patients in a University Hospital: Performance of MALDI-TOF MS-Based Identification, Antimicrobial Susceptibilities, and Baseline Patient Characteristics. Microb Drug Resist. 2018; Jul/Aug; 24(6): 816-821. doi: 10.1089/mdr.2017.0206.

22. Chaponda M., Shaukat A., Dulli M. W. et al. Elizabethkingia meningoseptica Infection in COVID-19 Patients. Cureus. 2022; Oct;14(10): e30337. doi: 10.7759/cureus.30337.

23. Hashmi A. W., Ahmad M., Israr M. M. et al. Multi-Drug-Resistant Elizabethkingia meningoseptica: A Rare Cause of Late-Onset Sepsis in a Preterm Neonate. Cureus. 2023; Jan;15(1): e34361. doi: 10.7759/cureus.34361.